Switch to fixed-dose doravirine (100 mg) and islatravir (0.25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial. (linkinghub.elsevier.com)

Authors: Colson AE … Lahoulou R Journal: The Lancet Published: 2026-02-07 DOI: https://doi.org/10.1016/S0140-6736(25)01948-8